Laura Panjwani | Authors


Expert Addresses Questions Surrounding Regorafenib and TAS-102 in mCRC Treatment

January 06, 2017

Tanios Bekaii-Saab, MD, discusses questions regarding regorafenib and TAS-102 in mCRC, compares the mechanisms of action and toxicities of both therapies, and shares his views on the optimal sequencing of the 2 agents.

Clarity Still Needed on Cetuximab Benefit in mCRC, Expert Says

December 23, 2016

Alan P. Venook, MD, discusses several of the big queries that remain in mCRC and the possible explanations for survival differences between left- and right-sided tumors. He also explained how answering these questions could pave the way for more novel treatment approaches.